The Intestinal Dysbacteriosis in the Pathogenesis of Necrotizing Enterocolitis

NCT ID: NCT05619055

Last Updated: 2022-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-05

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study Description

The goal of this observational study is to detect intestinal flora and the metabolic products in premature infants diagnosed as necrotizing enterocolitis. The main questions it aims to answer are:

* 1\. Whether there is intestinal flora in the stool of premature infants.
* 2\. Are there dysregulated intestinal flora and their metabolic products in premature infants diagnosed as necrotizing enterocolitis.
* 3\. The detailed role and underlying mechanism of the intestinal dysbacteriosis and the metabolic products in premature infants diagnosed as necrotizing enterocolitis.

Participants, premature infants diagnosed as necrotizing enterocolitis (NEC group), will be asked to collect stool (usually 2 times) for intestinal flora analysis.

If there is a comparison group: Researchers will compare premature infants without necrotizing enterocolitis (control group) to see if their intestinal flora and the metabolic products also changed as their NEC counterparts.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

When the patients is hospitalized in neonatology, we screen the premature infants according to the selection criteria and exclusion criteria. After sighed the informed consent, they are classified into two groups: premature infants diagnosed as necrotizing enterocolitis (NEC group) and premature infants without necrotizing enterocolitis (control group). Their stool and blood (usually 2 times ) are collected for intestinal flora and FABP (including L-FABP and I-FABP) analysis, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Necrotizing Enterocolitis of Newborn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

neonate with necrotizing enterocolitis

premature infants diagnosed as necrotizing enterocolitis

Routine treatment

Intervention Type OTHER

Antibiotics, intravenous fluids and symptomatic supportive treatment.

neonate without necrotizing enterocolitis

premature infants without necrotizing enterocolitis

Routine treatment

Intervention Type OTHER

Antibiotics, intravenous fluids and symptomatic supportive treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Routine treatment

Antibiotics, intravenous fluids and symptomatic supportive treatment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinical diagnosis of Necrotizing Enterocolitis,
* gestational age \<37 weeks,
* body weight 1,000-2,500 g,
* postnatal Apgar score ≥7,
* initial oral feeding tolerance.

Exclusion Criteria

* serious hereditary or other serious diseases, such as heart, lung and abdominal malformations ,
* early or late onset septicemia,
* early use of antibiotics in the newborn,
* serious adverse reactions caused by probiotics.
Minimum Eligible Age

5 Days

Maximum Eligible Age

2 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zuohui Zhao

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zuohui Zhao

Associate professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zuohui Zhao, Dr

Role: PRINCIPAL_INVESTIGATOR

Shandong First Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital of Shandong First Medical University

Jinan, Shandong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zuohui Zhao, Dr

Role: CONTACT

0086-531-89268509

Jiahui Li, Dr

Role: CONTACT

0086-531-89268508

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Wenjiao Jiao

Role: primary

0086-531-89269891

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YXLL-KY-2022(018)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.